[Extension of beta-lactamases producing bacteria is a worldwide concern].

Abstract

Since 2000's, community extended-spectrum beta-lactamases (ESBL) producing bacteria have spread worldwide, i.e. mostly Escherichia coli that produce ESBL such as CTX-M enzymes. Previous cephalosporins and fluoroquinolones usage are the two most frequent risk factors identified in patients that harbor ESBL-producing bacteria. In addition surveys have shown an alarming trend of associated resistance to others classes of antimicrobial agents among isolates. The emergence of ESBL-producing isolates limits the therapeutic options considerably. For serious systemic infections caused by ESBL-producing bacteria, carbapenems should be regarded as drugs of choice. Preventing the spread and appropriately managing these infections caused by community acquired ESBL producing bacteria have become mandatory.

• Authors: Jean-Ralph Zahar, Emmanuelle Bille, David Schnell, Fanny Lanternier, Frédéric Mechai, Virginie Masse, Xavier Nassif, Olivier Lortholary
• Journal: Medecine sciences : M/S (Med Sci (Paris)) Vol. 25 Issue 11 Pg. 939-44 (Nov 2009) ISSN: 0767-0974 [Print] France
• Vernacular Title: Diffusion communautaire des entérobactéries sécrétrices de bêta-lactamase à spectre élargi (EBLSE).
• PMID: 19951668 (Publication Type: Journal Article, Review)

Chemical References

• beta-Lactamases

Topics

• Bacteria (enzymology, pathogenicity)
• Bacterial Infections (epidemiology)
• Escherichia coli (enzymology)
• Escherichia coli Infections (epidemiology)
• Humans
• Klebsiella Infections (epidemiology)
• Klebsiella pneumoniae (enzymology)
• beta-Lactamases (biosynthesis)